Back to top

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

Canaccord analyst Edward Nash says AbbVie’s (ABBV) reported $10.9B takeover of Apogee Therapeutics (APGE) equates to roughly $144 per share. Apogee...

Read full article here »